表紙
市場調查報告書

腫瘤壞死因子受體超家族成員9 (TNFRSF9):開發平台分析

Tumor Necrosis Factor Receptor Superfamily Member 9 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 359843
出版日期 內容資訊 英文 169 Pages
訂單完成後即時交付
價格
腫瘤壞死因子受體超家族成員9 (TNFRSF9):開發平台分析 Tumor Necrosis Factor Receptor Superfamily Member 9 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 169 Pages
簡介

本報告提供以腫瘤壞死因子受體超家族成員9 (TNFRSF9) 為標的的藥物之適應症,開發階段,作用機制,給藥途徑及各分子類型分析,提供您藥物的藥理作用相關記述,迄今的研究開發趨勢,最新的新聞和發表,藥物的主要開發企業概要,休止/中止的計劃等資訊。

簡介

  • 調查範圍

腫瘤壞死因子受體超家族成員9概要

治療藥的開發

腫瘤壞死因子受體超家族成員9:開發中的產品 - 各開發階段

腫瘤壞死因子受體超家族成員9:開發中的產品 - 各治療範圍

腫瘤壞死因子受體超家族成員9:開發中的產品 - 各適應症

腫瘤壞死因子受體超家族成員9:開發中產品概況

  • 初期階段的產品

腫瘤壞死因子受體超家族成員9:企業開發中的產品

腫瘤壞死因子受體超家族成員9:大學/機關開發中的產品

腫瘤壞死因子受體超家族成員9:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

腫瘤壞死因子受體超家族成員9治療藥開發企業

  • Apogenix GmbH
  • BioInvent International AB
  • Pfizer Inc.
  • Pieris Pharmaceuticals, Inc.

藥物簡介

腫瘤壞死因子受體超家族成員9:暫停中的計劃

腫瘤壞死因子受體超家族成員9:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2075TDB

Summary

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) pipeline Target constitutes close to 55 molecules. Out of which approximately 51 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 9 - Pipeline Review, H2 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD137 is a member of the tumor necrosis factor (TNF) receptor family. CD137 is expressed by activated T cells (but to a larger extent on CD8 than on CD4 T cells). CD137 are involved in the regulation of a wide range of immune activities. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 12, 26 and 7 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.

Report covers products from therapy areas Oncology which include indications Solid Tumor, Colorectal Cancer, Non-Small Cell Lung Cancer, Diffuse Large B-Cell Lymphoma, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Bladder Cancer, Colon Carcinoma, Follicular Lymphoma, Hematological Tumor, Lung Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Cervical Cancer, Colon Cancer, Endometrial Cancer, Leukemia, Mantle Cell Lymphoma, Metastatic Cancer, Ovarian Cancer, Prostate Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Adenocarcinoma Of The Gastroesophageal Junction, Advanced Malignancy, Anal Cancer, B-Cell Chronic Lymphocytic Leukemia, Breast Cancer, Burkitt Lymphoma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Esophageal Cancer, Gastroesophageal (GE) Junction Carcinomas, Gliosarcoma, Gynecological Cancer, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Kidney Cancer (Renal Cell Cancer), Lymphoma, Malignant Mesothelioma, Metastatic Lung Cancer, Multiple Myeloma (Kahler Disease), Nasopharyngeal Cancer, Pancreatic Cancer, Primary CNS Lymphoma, Primary Mediastinal B-Cell Lymphoma, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Secondary CNS Lymphoma, Squamous Cell Carcinoma, Transitional Cell Cancer (Urothelial Cell Cancer) and Triple-Negative Breast Cancer (TNBC).

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)
  • The report reviews Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Overview
  • Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Companies Involved in Therapeutics Development
  • AbClon Inc
  • ABL Bio Inc
  • Adagene (Suzhou) Ltd
  • Agenus Inc
  • Alligator Bioscience AB
  • Apogenix AG
  • Aptevo Therapeutics Inc
  • Avacta Life Sciences Ltd
  • Bicycle Therapeutics Plc
  • BioNTech SE
  • Bristol-Myers Squibb Co
  • Clover Biopharmaceuticals
  • Compass Therapeutics LLC
  • Crescendo Biologics Ltd
  • Eutilex Co Ltd
  • F. Hoffmann-La Roche Ltd
  • FasCure Therapeutics LLC
  • Hutchison MediPharma Ltd
  • I-Mab Biopharma Co Ltd
  • Inhibrx Inc
  • Juno Therapeutics Inc
  • KAHR medical Ltd
  • LeadArtis SL
  • Leads Biolabs Inc
  • Lyvgen Biopharma Ltd
  • MacroGenics Inc
  • Merus NV
  • Molecular Partners AG
  • Numab Innovation AG
  • Pfizer Inc
  • Pieris Pharmaceuticals Inc
  • Rubius Therapeutics Inc
  • Torque Therapeutics Inc
  • Xcella Biosciences Inc
  • Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Drug Profiles
  • ABL-501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ABL-503 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ADG-106 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Appendix

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1)
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..8), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by AbClon Inc, H2 2019
  • Pipeline by ABL Bio Inc, H2 2019
  • Pipeline by Adagene (Suzhou) Ltd, H2 2019
  • Pipeline by Agenus Inc, H2 2019
  • Pipeline by Alligator Bioscience AB, H2 2019
  • Pipeline by Apogenix AG, H2 2019
  • Pipeline by Aptevo Therapeutics Inc, H2 2019
  • Pipeline by Avacta Life Sciences Ltd, H2 2019
  • Pipeline by Bicycle Therapeutics Plc, H2 2019
  • Pipeline by BioNTech SE, H2 2019
  • Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Pipeline by Clover Biopharmaceuticals, H2 2019
  • Pipeline by Compass Therapeutics LLC, H2 2019
  • Pipeline by Crescendo Biologics Ltd, H2 2019
  • Pipeline by Eutilex Co Ltd, H2 2019
  • Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
  • Pipeline by FasCure Therapeutics LLC, H2 2019
  • Pipeline by Hutchison MediPharma Ltd, H2 2019
  • Pipeline by I-Mab Biopharma Co Ltd, H2 2019
  • Pipeline by Inhibrx Inc, H2 2019
  • Pipeline by Juno Therapeutics Inc, H2 2019
  • Pipeline by KAHR medical Ltd, H2 2019
  • Pipeline by LeadArtis SL, H2 2019
  • Pipeline by Leads Biolabs Inc, H2 2019
  • Pipeline by Lyvgen Biopharma Ltd, H2 2019
  • Pipeline by MacroGenics Inc, H2 2019
  • Pipeline by Merus NV, H2 2019
  • Pipeline by Molecular Partners AG, H2 2019
  • Pipeline by Numab Innovation AG, H2 2019
  • Pipeline by Pfizer Inc, H2 2019
  • Pipeline by Pieris Pharmaceuticals Inc, H2 2019
  • Pipeline by Rubius Therapeutics Inc, H2 2019
  • Pipeline by Torque Therapeutics Inc, H2 2019
  • Pipeline by Xcella Biosciences Inc, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019